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Abstract 
 Introduction: The diagnostic of prostate cancer (PCa) using serum-
based prostate specific antigen (PSA) has some limitations due to false-
positive and  negative results. The purpose of our study was to analyse the 
hypermethylation of three genes from plasma samples and to determine the 
feasibility of these genes to aid as biomarkers in detecting PCa in plasma by 
noninvasive methods. 
Materials and Methods: Genomic DNA was extracted from the peripheral 
blood plasma of 74 patients with localized PCa. All the samples were 
examined for aberrant hypermethylation in retinoic acid receptor β variant 2 
(RARβ2), glutathione S-transferase P1 (GSTP1) and Ras association domain 
family 1 isoform A(RASSF1A) genes, using methylation-specific PCR 
(MSP), and the results were correlated with the clinicopathological 
parameters. 
Results: The percent of methylation of the analyzed genes was as follows: 
RARβ2 was found methylated in 54 cases (73 %), GSTP1 in 58 cases 
(78.4%), and RASSF1A was found methylated in all 74 cases (100%). 
Conclusion: Our study demonstrates that, using a panel of DNA methylated 
biomarkers aids the identification of PCa patients and with minimally 
invasive techniques , may yield information independent of serum PSA or 
the TNM stage. 
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Introduction 
 Prostate cancer (PCa) represents one of the most common 
malignancies among men worldwide, with an estimated 193.000 new cases 
and 27.500 PCa related deaths in the United States in 2009 (Jemal et 
al,2009). It is one of the most complicated human tumors and, like many 
other malignancies, arises from progressive genetic and epigenetic 
alterations. Since the introduction of the serum prostate-specific antigen 
(PSA) into clinical use, there has been a significant increase in the diagnosis 
of men at an early stages of the disease. Treatment decisions in patients with 
advanced tumors are based on older and known prognostic factors (Gleason 
score, pathological stage, serum PSA variables). Epigenetic changes 
represent changes in gene expression which are not caused by alterations in 
the primary sequence of the nucleotides that compose the gene. Epigenetic 
mechanisms such as DNA methylation and histone modification play an 
essential role in many molecular and cellular alterations associated with the 
development and progression of PCa (Li LC, 2005). Epigenetic events have 
been demonstrated to be an early event in cancer development, and thus can 
be used in assessing the risk of cancer developing (Alumkal JJ 2008). One 
possible approach to the detection of PCa is through analysis of the 
circulating DNA from cancer cells. In seeking more specific biomarkers, 
several studies have shown that DNA abnormalities may bedetected in the 
plasma and the serum of cancer patients are those of the gene promoter 
hypermethylation. The presence of gene promoter hypermethylation in the 
serum and plasma DNA has also been demonstrated in patients with different 
types of cancers,also including prostate cancer(Schwarzenbach H et al, 
2009). 
 The aim of our study was to evaluate the methylation status of the 
promoter regions of 3 cancer-related genes which are involved in DNA 
repair (GSTP1), cell cycle regulation (RASSF1A) and the mediator of the 
antiproliferative effect of retinoid (RARbeta2), in the prostate, according to 
the degree of malignancy . 
Materials and methods 
 The study was conducted with the participation of 74 men which had 
a prostate biopsy to establish their diagnostic by an urologist. They were 
hospitalized at the Urology Department of Clinical County Emergency 
Hospital, Timisoara,Romania.A transrectal ultrasound-guided prostate 
biopsy was made with a spin and in sextant. The exam was made with local 
anaesthesia on the recumbent patient. The clinicopathological characteristics 
of the patients are presented in Table 1. The identity of each patient was 
confidential and through the anatomopathological exam, the stage of cancer 
development was diagnosed and could be correlated.The study was 
conducted according to the Helsinki Statement,2008. 
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Table 1.  Clinicopathological characteristics 
  n 
Number of patients  74 
TNM stage   
I/II  47 
III  23 
IV  4 
Gleason score   
5  18 
6  13 
7  13 
8  5 
9  14 
10  1 
PSA, ng/ml   
≤4  29 
>4  45 
Mean   25.4 
Mean age, years  73.4 
 
Sample collection and genomic DNA isolation  
 Blood samples were collected from all the patients included in the 
study. To obtain the plasma for further DNA isolation, we centrifugated the 
blood samples for 10 minutes at 3500 X g. Genomic DNA was extracted 
from the plasma using the QIAmp® DNA Mini Kit, according to the 
manufacturer’s instructions (Qiagen, Hilden, Germany). Each DNA sample 
was quantified using Nanodrop 8000 (LabTech®), measuring the optical 
density ratio at 260/280 nm. 
 Bisulfite treatment and MS-PCR analysis 
 We used 2 sets of primers, methylated and unmethylated, to amplify 
each region of interest: one pair of primers was used to recognize the 
sequence in which the CpG sites were unmethylated, and the other pair of 
primers was used to recognize the sequence in which the CpG sites were 
methylated. For each set of PCR we used negative control samples, without 
DNA. The procedure takes advantage of the bisulfite-mediated chemical 
conversion of cytosine to uracil followed by PCR using primers designed to 
distinguish methylated DNA from unmethylated DNA. The sequences of the 
primers were designed by MethPrimer software . Each modification was 
checked using a verification method prescribed by the manufacturer. PCR 
was carried out in a total volume of 30μL per reaction containing 0.5μL of 
AmpliTaq (Applied Biosystems®), 3μL of gene probes , 0.5μL of dNTP , 3 
μL of PCR buffer (10X) , 19.3 μL of distilled water and 4μL of each DNA 
sample. Each PCR reaction was subjected under the following conditions: 
denaturation at 95 C for 10 min, and 45 cycles of the following profile: 30 s 
at 94, 30 s at 55C, and 30 s at 72C. The PCR products were then analyzed by 
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electrophoresis on a 2.5 % agarose gel and stained with ethidium bromide 
and visualized by a UV transilluminator. A 100 bp DNA Ladder (Zymo 
Research, CA,USA) was used. DNA was considered methylated if a PCR 
product using unmethylated specific primers was absent. When the PCR 
product was present using both unmethylated-specific primers and 
methylated-specific primers, it meant that between 25% and 75% of the gene 
promoter could be considered methylated. 
Statistical Analysis 
 To compare the clinical factors among the tumors demonstrating 
hypermethylation versus nonmethylation status in this study, we used 
ANOVA with the Dunnett method for the continuous variables and the χ2 
test for the categorical variables,a P value < 0.05 was considered significant. 
Results 
 Frequency of hypermethylation of tumor-related genes in prostate 
samples: 
 Methylation of the involved genes in PCa was as follows: RARβ2 in 
54 cases (73 %), GSTP1 in 58 cases(78.4%), and RASSF1A was found 
methylated in all 74 cases (100%). In comparison, we found that the 
unmethylated genes in the serum samples were lower, for example:GSTP1 
was unmethylated in only 16 cases (21.6%), RARβ2 in 20 cases (27%) and 
RASSF1A was not found unmethylated at all. Healthy males did not present 
these methylated circulating DNA biomarkers in their plasma samples under 
optimal assay conditions. 
 
Figure no.1. Distribution of hypermethylated genes (RASSF1A,GSTP1,RARβ2) 
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Correlation between the methylated DNA and serum prostate specific 
antigen (PSA): 
 The mean serum PSA concentration in patients with hypermethylated 
tumor-related genes (GSTP1, RASSF1A, RARβ2) was significantly higher 
than in patients without hypermethylated genes (P=0.003, 0.021 and <0.005, 
respectively).Moreover, patients who had more than 1 tumor-related gene 
methylated presented serum PSA concentrations significantly higher than 
patients without circulating hypermethylated DNA (P=0.003). 
 
Figure no.2. Correlation between hypermethylated genes and serum PSA values 
 
is minimally invasive and can be repeated to monitor different 
changes which occur during the disease Correlation between Gleason score 
and circulating methylated DNA: 
 We correlated the Gleason score with the methylation status of the 3 
genes. The mean PCa Gleason score in patients with hypermethylated 
GSTP1, RASSF1A and RARβ2 was significantly higher (P=0.019, 0.048 and 
0.015, respectively) than in patients without hypermethylated DNA. Patients 
with ≥ 1 hypermethylated tumor-related gene presented a serum PSA 
concentration which was significantly greater than in patients without 
circulating DNA (P=0.003). 
Discussion 
 Diagnosis of PCa by needle biopsy in small moderate-grade cancers 
can be difficult. Needle biopsies contain small samples of prostatic tissue and 
often only a few fragments of malignant gland( Maruyama et al, 2002). In 
this case, manypatients are subjected to multiple biopsies in examinations 
before a correct diagnostic is made. The finding of tumor-derived DNA in 
the circulation of cancer patients has inspired further efforts to develop DNA 
based assays capable of detecting evidence of cancer using serum or plasma 
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samples (Altimari et al, 2008). Unlike tissue biopsy, blood sampling has a 
number of advantages because it progression and can also be used to detect 
recurrence. The only blood-based non-invasive screening method for PCa 
detection is serum PSA measurement which is of limited value because of 
the false positives or negatives results (Bock et al, 2004). In our study of 
circulating DNA from patients with the diagnosis of PCa, we examined the 
hypermethylation of the promoter regions of 3 tumor-related genes : 
RASSF1A,GSTP1 and RARβ2, which were reported to be hypermethylated 
in a percentage of 37%-99%,53%-75% and 55%-92% respectively in PCa 
samples(Enokida et al, 2005).It has been demonstrated in the past that, 
GSTP1 is found hypermethylated in about 30%-97% of PCa tissue (Ellinger 
et al, 2008), but not many reports are published of the hypermethylation of 
RASSF1A and RARβ2 in plasma samples. In our study, we found that 
RASSF1A, GSTP1 and RARβ2 were hypermethylated in 100% of 
RASSF1A (74 of 74), 78.4% of GSTP1(58 of 74) and 73% of RARβ2 (54 of 
74). By combination, the 3 biomarkers identified 62% of patients with PCa. 
Other studies, used a panel of 9 biomarkers from urine sediments obtained 
from PCa patients, to detect the promoter region hypermethylation in urinary 
DNA (Hoque et al, 2005).  
 In our study, we found a significant correlation between serum PSA 
concentration and the methylation positive group (P=0.03; P=0.01 and 
P=0.025). We consider that these patients represent PCa cases which could 
be missed if the diagnosis were based only on serum PSA measurement in 
the absence of digital rectal examination (Hoque et al, 2009). We also noted 
that, the frequency of hypermethylation increased directly with the TNM 
stage of the disease. We observed that, RASSF1A and GSTP1 were also 
methylated in patients in stage IV of the disease, concluding that it is 
possible for these genes to be implicated in the processes of invasion and 
metastasis ( Phe et al,2010 and Gurban et al, 2012). 
 We have demonstrated here the potential of adding gene methylation 
tests to histologic examination for the precise diagnosis of PCa. 
Conventional methylation specific PCR assays of the key PCa genes should 
be incorporated into diagnostic trials to help the early detection of the 
disease. Validation of these studies could change the standard evaluation of 
tissue biopsies after PSA screening. 
Conclusion 
 Our study , tested the ability of a panel of three methylation 
biomarkers to aid the improve sensitivity of standard histology for PCa 
detection in needle biopsies. Conventional methylation specific PCR assays 
of the key PCa genes should be incorporated into diagnostic trials to help the 
early detection of the disease. Validation of these studies could change the 
standard evaluation of tissue biopsies after serum PSA screening. 
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